Atea Pharmaceuticals Inc represents values of innovation, collaboration, and dedication to improving global health. With a strong corporate philosophy focused on advancing antiviral therapies, the company is committed to delivering transformative solutions for infectious diseases. Atea Pharmaceuticals prioritizes research and development, employing cutting-edge science and technology to develop novel therapeutics that target viral replication. By focusing on the fundamental biology of viruses, Atea Pharmaceuticals aims to provide effective antiviral therapies that address unmet medical needs. Through its commitment to excellence and patient-centric approach, Atea Pharmaceuticals strives to make a significant impact in the field of infectious diseases.

Atea Pharmaceuticals Inc is primarily present in the United States, with headquarters in Boston, Massachusetts. As a biopharmaceutical company focused on discovering and developing antiviral therapeutics, Atea Pharmaceuticals Inc has a strong presence in the healthcare sector in the US. With a dedication to advancing innovative treatments, Atea Pharmaceuticals Inc is actively involved in research and collaborations within the US healthcare industry.

Atea Pharmaceuticals Inc has achieved significant milestones in its journey. Some notable accomplishments include the successful completion of Phase 1 clinical trials for its antiviral candidate, AT-527. The company also obtained Fast Track designation from the U.S. FDA for AT-527 as a potential treatment for COVID-19. Atea Pharmaceuticals Inc formed strategic collaborations, such as the partnership with Roche to develop and distribute AT-527 globally. Additionally, the company went public on the Nasdaq stock exchange, raising funds to further progress its antiviral programs. These accomplishments reflect Atea Pharmaceuticals Inc's dedication to advancing innovative therapies and its potential for growth in the biopharmaceutical industry.

Atea Pharmaceuticals Inc. is a leading biopharmaceutical company that focuses on discovering and developing novel antiviral therapies. With a rich history and background, Atea Pharmaceuticals was founded in 2014 and is headquartered in Boston, Massachusetts, USA. The company is dedicated to addressing the urgent global health challenges posed by viral diseases. Atea Pharmaceuticals has a strong pipeline of innovative antiviral therapeutics that specifically target RNA-based viruses, including the current focus on developing a potential oral direct-acting antiviral for the treatment of COVID-19. With its cutting-edge science and committed team, Atea Pharmaceuticals remains at the forefront of developing groundbreaking therapies to combat viral infections.

The main competitors of Atea Pharmaceuticals Inc in the market are other pharmaceutical companies involved in antiviral therapeutics development and production. Some prominent competitors in this space include Gilead Sciences Inc, Merck & Co Inc, Johnson & Johnson, GlaxoSmithKline Plc, and AbbVie Inc. These companies operate in similar therapeutic areas and may have overlapping product portfolios targeting viral infections, including COVID-19. Atea Pharmaceuticals Inc faces competition in the race for the development of effective antiviral treatments, with each competitor striving to create innovative solutions to combat viral diseases.

Atea Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

Atea Pharmaceuticals Inc is a biopharmaceutical company with a focus on discovering, developing, and commercializing antiviral therapeutics. Their business model is centered around targeting the replication process of viral infections, including RNA viruses like SARS-CoV-2 (COVID-19). By developing innovative nucleotide analogs, Atea aims to address unmet medical needs and provide effective treatments for viral diseases. As a leading pharmaceutical company, Atea Pharmaceuticals Inc combines cutting-edge science, strategic partnerships, and a patient-centric approach to revolutionize antiviral therapies and improve global healthcare.

Atea Pharmaceuticals KGV ir -1,40.

Atea Pharmaceuticals KUV ir 0.

AlleAktien kvalitātes vērtējums Atea Pharmaceuticals ir 1/10.

Pašreiz nevar aprēķināt apgrozījumu Atea Pharmaceuticals.

gaidāmā Atea Pharmaceuticals peļņa ir -219,15 milj. USD.

Atea Pharmaceuticals Inc is an innovative company specializing in the research and development of antiviral therapies to combat life-threatening virus infections. The company was founded in 2014 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals' business model is based on three main divisions: research and development, medical marketing and sales, and clinical research. In the research and development department, new antiviral medications are designed, researched, and tested to develop innovative therapies against viruses such as RNA viruses, influenza, SARS-CoV-2, and many more. Atea Pharmaceuticals has specialized particularly in RNA viruses, including Respiratory Syncytial Virus (RSV) and Hepatitis C Virus (HCV). The company has a special focus on viral diseases that can be particularly severe in certain patient populations, such as immunocompromised individuals, pregnant women, and older people. Products from Atea Pharmaceuticals include AT-527, a direct-acting antiviral therapy developed for the treatment of RNA viruses, including COVID-19. AT-527 is currently in Phase 2 clinical trials (as of August 2021). Another product in the portfolio is AT-752, a potential universal influenza virus blocker that is still in the preclinical development phase. Furthermore, Atea Pharmaceuticals focuses on collaborating with partner companies to develop and market antiviral therapies. For example, Atea has partnered with AbbVie to work together on the development of AT-527. To maximize the success of its products in practice, Atea Pharmaceuticals also employs an extensive marketing and sales plan. This includes efforts to publish key results and performance data from current and future clinical studies. As a result, positive results from a Phase 1 clinical study of AT-527 were published in December 2020, which found a significant reduction in viral load in COVID-19 patients. A Phase 2 clinical trial for AT-527 is currently underway. In conclusion, Atea Pharmaceuticals' business model focuses on the development of innovative antiviral therapies, particularly for RNA viruses, to combat life-threatening virus infections. With this goal in mind, research and development, clinical research, and medical marketing and sales are conducted comprehensively. The company has a partnership with AbbVie and offers products like AT-527, while continuing to work on the development of new products.

Atea Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Atea Pharmaceuticals vai uzņēmums nedod dividendes.

Atea Pharmaceuticals ISIN ir US04683R1068.

Atea Pharmaceuticals simbols ir AVIR.

Pēdējo 12 mēnešu laikā Atea Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Atea Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Atea Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Atea Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Atea Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Atea Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Atea Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 22.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 22.09.2024..

Pēdējās dividendes izmaksa notika 22.09.2024..

Gadā 2023, Atea Pharmaceuticals izmaksāja 0 USD dividendes.

Atea Pharmaceuticals dividendes tiek izmaksātas USD.